Ziarco Group is a privately held biotechnology company focused on treatments for inflammatory skin disorders.
Through the deal, Novartis will gain access to Ziarco’s investigational oral treatment for moderate-to-severe eczema.
Financial details of the transaction were not disclosed.
More articles on supply chain:
McKesson, Infor form go-to-market partnership: 3 things to know
American Red Cross needs donors amid seasonal blood shortage
Amazon conducts first drone delivery to a customer
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
